MiniMed™ 780G system

Footnotes

¶ Due to inherent real-world study limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.

† Due to inherent real-world study limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences. Overnight period: 3:00 AM- 6:00 AM. Number of users with ≥10 days of sensor glucose data; Optimal settings are glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours and used >95% of the time.

‡ Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.

‖ Refers to SmartGuard^™ technology. Individual results may vary.

◊ Refers to auto correct, which provides bolus assistance. Can deliver all correction doses automatically without user interaction, feature can be turned on and off.

References

1. Adults, T1 and parents of children with T1 diabetes < 18 years were surveyed

2. Individual results may vary.

3. dQ&A US Patient Voice Q2 2025.p. 77. N=215

4. Arrieta A, et al. Diabetes Obes Metab. 2022;10.1111/dom.14714 .

5. McVean, et al. 972-P: Hyperglycemia from Real-World Dawn Phenomenon Is Nearly Eliminated with the MiniMed 780G System (MM780G). Diabetes 14 June 2024; 73 (Supplement_1): 972–P. https://doi.org/10.2337/db24-972-P

6. Data on file, Abbott Diabetes Care, Inc.

Important Safety Information: MiniMed^™ 780G system with SmartGuard^™ technology with Instinct sensor, Simplera Sync^™ sensor, and Guardian^™ 4 sensor

The MiniMed^™ 780G system is intended for the continuous delivery of basal insulin at selectable rates and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose values in the fluid under the skin.

The MiniMed^™ 780G System includes SmartGuard^™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values. The system is intended for use with connected sensors, including the Simplera Sync^™ and Guardian^™ 4 sensors and integrated continuous glucose monitors, including the Instinct sensor, each of which has different wear-time, form factor, insertion site, and other distinguishing characteristics that relate to sensor performance. Consult the appropriate sensor user guide when using the system. Discuss treatment decisions with your HCP.

WARNING: Do not use the MiniMed^™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed^™ 780G system.

WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard^™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed^™ 780G system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including accessories and additional important safety information concerning indications, contraindications, warnings and precautions associated with the system and its components, please consult https://www.minimed.com/en-us/important-safety-information/ and the appropriate user guides at https://www.minimed.com/en-us/support/download-library/.

©2026 Medtronic. MiniMed and MiniMed logo are trademarks of Medtronic MiniMed, Inc. The sensor shape and appearance, Abbott, and "a" logo are marks and/or designs of the Abbott group of companies in various territories and used under license. Sensor image ©2026 Abbott. ^™*Third–party brands are trademarks of their respective owners.

DreaMed Diabetes is a trademark of DreaMed Diabetes, Ltd. The MiniMed^™ 780G system algorithm includes technology developed by DreaMed Diabetes.